Ehrly, 1984 - Google Patents
Evaluation of enzymatic defibrinogenationEhrly, 1984
- Document ID
- 14034303856208490756
- Author
- Ehrly A
- Publication year
- Publication venue
- Clinical Hemorheology and Microcirculation
External Links
Snippet
The term therapeutic hypofibrinogenimia means a decrease in fibrinogen concentration in the circulating blood in order to treat vascular diseases. Reduction in fibrinogen cencentration can be done by different ways, so by fibrinogenolysis using Streptokinase or …
- 230000003536 defibrinogenating effect 0 title abstract description 16
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pederzoli et al. | Efficacy of octreotide in the prevention of complications of elective pancreatic surgery | |
| Eriksson et al. | Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis | |
| ZA989385B (en) | Methods for treating hypercoagulable states or acquired protein C deficiency. | |
| Olinger et al. | Use of ancrod in acute or progressing ischemic cerebral infarction | |
| KR890012666A (en) | Treatment of Kidney Disease | |
| White et al. | Intravenous valproate associated with significant hypotension in the treatment of status epilepticus | |
| Lowe et al. | Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg | |
| Poggesi et al. | Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis | |
| JP2006525270A (en) | Intravenous injection of non-neurotoxic plasminogen activator for the treatment of cerebral infarction | |
| PT1997510E (en) | Non-neurotoxic plasminogen-activating factors for treating strokes | |
| Rapold et al. | Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator | |
| Ehrly | Evaluation of enzymatic defibrinogenation | |
| Bode et al. | Absence of drug interaction between heparin and nitroglycerin: randomized placebo-controlled crossover study | |
| Langer et al. | Ultrastructural study of the dermal microvasculature in patients undergoing retrograde intravenous pressure infusions | |
| Rosenthal et al. | Hyperbaric oxygenation in peripheral ischaemic lesions in infants. | |
| Italian Study Group Pederzoli P Clinica Chirurgica, Policlinico Borgo Roma, Verona, Italy Bassi C Dr Clinica Chirurgica, Policlinico Borgo Roma, Verona, Italy Falconi M Clinica Chirurgica, Policlinico Borgo Roma, Verona, Italy Camboni MG Sandoz Prodotti Farmaceutici SpA, Milan, Italy | Efficacy of octreotide in the prevention of complications of elective pancreatic surgery | |
| Chesterman et al. | Streptokinase therapy in acute major pulmonary embolism | |
| Andreozzi et al. | Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class | |
| US3725553A (en) | Method for activating the blood fibrinolysis by administration of 2-amino-ethanesulphonic acid or salts thereof | |
| Keber | The increase of leg fibrinolytic potential after reduction of hydrostatic stimulus | |
| ZHUO et al. | Comparison of incidence, mortality and treatment of acute myocardial infarction in hospitals in Japan and China | |
| RU2147230C1 (en) | Method for preventing thromboembolism complications in surgical patients | |
| Beanlands et al. | Angiotensin ii in the treatment of shock following myocardial infarction | |
| EA013837B1 (en) | A METHOD FOR TREATING A HUMAN CEREBRAL STROKE COMPRISING ADMINISTERING PLASMINOGEN ACTIVATORS α1 FROM DESMODUS ROTUNDUS | |
| Storti et al. | Epsilon-aminocaproic acid for synovectomy in haemophilic patients |